Related Experiment Video

Updated: May 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Dabigatran use in mechanical heart valve patients

Farnoosh Zough1, Javad Tafreshi, Ramdas G Pai

  • 1Loma Linda University School of Pharmacy, Loma Linda, CA, USA.

Future Cardiology
|December 19, 2013
PubMed

Insights

Novel oral anticoagulants like dabigatran are not recommended for mechanical heart valves. A clinical trial found dabigatran increased risks of stroke and bleeding compared to warfarin, leading to early termination.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Current guidelines lack recommendations for novel oral anticoagulants (NOACs), such as dabigatran, in patients with mechanical heart valves.
  • Preliminary research in atrial fibrillation patients and animal models suggested a potential role for dabigatran in this population.
  • This study addresses the clinical question of dabigatran's efficacy and safety in mechanical heart valve patients.

Purpose of the Study:

  • To investigate the efficacy and safety of dabigatran compared to warfarin in patients with mechanical heart valves.
  • To validate a specific dosing regimen for dabigatran in this patient group.
  • To assess the composite outcome of stroke, systemic embolism, myocardial infarction, and death.

Main Methods:

  • A prospective, randomized controlled Phase II clinical trial.
  • 252 patients were randomized in a 2:1 ratio to receive either dabigatran or warfarin.
  • The trial involved 39 centers across ten countries and was prematurely terminated.

Main Results:

  • The composite event rate (stroke, systemic embolism, myocardial infarction, death) was 8% for dabigatran versus 2% for warfarin (HR: 3.37; 95% CI: 0.76–14.95; p = 0.11).
  • Bleeding rates were significantly higher in the dabigatran group (27%) compared to the warfarin group (12%) (HR: 2.45; 95% CI: 1.23–4.86; p = 0.01).
  • The trial was stopped early due to safety concerns.

Conclusions:

  • Dabigatran demonstrated a higher risk of adverse events, including bleeding, compared to warfarin in patients with mechanical heart valves.
  • No additional benefits were observed with dabigatran use in this population.
  • Current evidence does not support the use of dabigatran for thromboembolic event prevention in patients with mechanical heart valves.

More Related Videos

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

722
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.1K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598